5 Key Takeaways

• 1

  SGLT2 inhibitors may significantly reduce the risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality in SLE and diabetes patients.

• 2

  The study analyzed data from 3,550 matched patients, with 1,775 pairs included in the final analysis, using the TriNetX clinical data platform.

• 3

  SGLT2 inhibitor users had a 45% lower risk of lupus nephritis and a 65% lower risk of all-cause mortality compared to nonusers over 5 years.

• 4

  The protective association of SGLT2 inhibitors remained consistent across various subgroups, including patients with chronic kidney disease.

• 5

  The study's limitations include potential selection bias and lack of biopsy confirmation for lupus nephritis diagnosis, emphasizing associations rather than causation.